Announcements

A Schedule 13G was filed on November 9, 2026, by The K2 Principal Fund, L.P. and three affiliated entities disclosing beneficial ownership of 241,100 Class A Ordinary Shares of Newbury Street II Acquisition Corp as of November 4, 2026.

Vir Biotechnology, Inc. filed a Form 8-K on November 9, 2026, disclosing topline results from its pivotal Phase 3 ECLIPSE 1 clinical trial and expanded Week 96 data from the Phase 2 SOLSTICE study, both evaluating elebsiran and tobevibart in adults with chronic hepatitis …

Empery Digital Inc. filed a Form 8-K on November 9, 2026, disclosing share repurchase activity for the week ended November 6, 2026, and providing an update on lease negotiations for its Midwest data center investment through EMHU LLC.

Ionis Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting financial results for the three and nine months ended on that date.

C3is Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing that the company effected a one-for-5 reverse stock split of its common stock, with the split becoming effective at 11:59 p.m. Eastern time on November 8, …

Vistagen Therapeutics, Inc. filed a Form 8-K on November 9, 2026, announcing a regulatory update following a Type C meeting with the U.S. Food and Drug Administration to discuss potential registrational paths for its lead product candidate, fasedienol, in social anxiety disorder.

Newell Brands Inc. filed a Form 8-K on November 9, 2026, disclosing that its Board of Directors voted on November 4, 2026, to expand the board from eight to nine members and elect William Newlands as a director, effective January 1, 2027.